Physician profile
Henning Rasmussen
NPI 1487649943
$1,644.04
in general payments reported to CMS, 2019-2025
18 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $34.43 · 2021: $145 · 2022: $569 · 2023: $211 · 2024: $170 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $530.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $352.72 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $289.26 | 2019-2022 | |
| Shockwave Medical, INC | $201.02 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| E.R. Squibb & Sons, L.L.C. | $138.34 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $135.51 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.48 | 2021-2023 | Jardiance |
| Pfizer INC. | $49.48 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $46.87 | 2021-2023 | Verquvo |
| Amgen INC. | $43.98 | 2019-2023 | Repatha |
| Scpharmaceuticals INC. | $41.55 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $26.55 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $26.49 | 2023 | Arcalyst |
| Abbott Laboratories | $24.98 | 2025 | Aveir |
| Chiesi USA, INC. | $24.04 | 2021-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $16.72 | 2019 | |
| Novo Nordisk INC | $16.00 | 2023 | |
| Penumbra, INC. | $12.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henning Rasmussen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.